The aim of our analyses was to evaluate whether the use of ESYSTA leads to improvements in self‐management and in glycemic control in insulin‐treated people with diabetes, expressed by a change in HbA1c (in percentage points). This evidence concerns the gene INS and diabetes mellitus.